Skip to main content

Drug Interactions between influenza virus vaccine, live and Spherulin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

coccidioidin skin test influenza virus vaccine, live

Applies to: Spherulin (coccidioidin skin test) and influenza virus vaccine, live

ADJUST DOSING INTERVAL: Reactivity to diagnostic skin test antigens may be temporarily depressed in patients who have recently been vaccinated with live virus vaccines. Falsely insignificant or false-negative results may occur in such patients.

MANAGEMENT: Clinicians should be aware of the potential for falsely insignificant or false-negative results when performing delayed-hypersensitivity skin testing on patients who have recently received live virus vaccines. Diagnostic skin test antigens should generally be administered before or 4 to 6 weeks after immunization. It is recommended to refer to local guidelines or prescribing information.

References

  1. (2001) "Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen)." Aventis Pharmaceuticals
  2. (2001) "Product Information. Multitest CMI (skin test antigens, multiple)." Aventis Pharmaceuticals
  3. "Product Information. Tuberculin Tine Test (tuberculin purified protein derivative)." Connaught Laboratories Inc

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.